Boston completes $425m divestment to Avista
This article was originally published in Clinica
Boston Scientific has completed the sale of its fluid management and venous access businesses to private New York equity firm Avista Capital Partners for $425m. An agreement for the all-cash deal was originally signed in December (see Clinica No 1287, p 1). The closing of the sale brings about the completion of Boston's plans to divest its five non-core businesses. Boston is currently undergoing major restructuring initiative to pull the company back into profitable growth. The Natick-Massachusetts-based company expects the divestment to result in after-tax gain of around $120m during the first quarter of 2008.
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.